Back to Journal

SM Journal of Pulmonary Medicine

The Overview of the Clinical Significance of Interferon-Gamma Release Assays for the Diagnosis of Tuberculosis

[ ISSN : 2574-240X ]

Abstract Introduction Prospective Strategies References
Details

Received: 16-Apr-2015

Accepted: 25-May-2015

Published: 12-Jun-2015

Yulu Gao¹#, Shencong Mei²#, Jun Wang⁴#, Zhonghua Liu⁶, Qinyun Li³, Zongshuai Gao³, Changtai Zhu³,⁶, and Yongning Sun⁵

¹Department of Laboratory Medicine, Kunshan Hospital Affiliated to Nanjing University of Traditional Chinese Medicine, Kunshan 215300, Jiangsu Province, China

²Department of Outpatient, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai 200233, China

³Department of Transfusion, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai 200233, China

?Department of Obstetrics and Gynecology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai 200233, China

?Department of Traditional Chinese Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai 200233, China

?Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China

#These authors contributed equally to this work

Corresponding Author:

Changtai Zhu Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, No. 507 Zhengmin Road, Shanghai 200433, China, Email: zct101@163.com

Yongling Sun Department of Traditional Chinese Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, No. 600 Yishan Road, Shanghai 200233, China, Email: ynsun2002@126.com

Keywords

Interferon-Gamma release assays; Latent active tuberculosis infection; Active tuberculosis; Tuberculosis

Abstract

Due to lack of the practical application guidelines for Interferon-Gamma Release Assays (IGRAs), the testing result of IGRAs may be misinterpreted in clinical practice in China. Therefore, we clarify some important issues related to IGRAs based on the available evidences in this review. The available data reveals that IGRAs can be used to assist the diagnosis of Latent TB Infection (LTBI) and combined with HIV infection; while for the definite diagnosis and therapeutic monitoring of active TB have no value. In addition, IGRAs showed no better performance than TST in low income countries. It should make practical guidelines to TB diagnostic tools and further strengthen the training and guide for the clinicians the low income countries, so as to more scientifically manage TB.

Introduction

As a novel potential tool to diagnose the Tuberculosis (TB) infection, the Interferon-Gamma Release Assays (IGRAs), mainly including Quanti FERON-TB Gold and T-SPOT.TB, have been widely used all around the world. In China, T-SPOT.TB has more commonly been applied to TB diagnosis in clinical practice in recent years. Compared with other TB tests, the assay costs more (about $100-$130) in China. However, due to lack of the practical guidelines for (IGRAs) in some countries, some clinicians don’t understand its exact clinical significance. Sometimes, the positive result of IGRAs is misinterpreted as a robust diagnostic criterion for active TB, resulting in an inappropriate anti-TB treatment. Therefore, it is essential to clarify some important issues related to IGRAs based on the available evidences as follows.

The clinical value in the diagnosis of Latent TB Infection (LTBI)

The meta-analysis results show that T-SPOT.TB appears to be more sensitive both Tuberculin Skin Test (TST) and QuantiFERON Gold in the diagnosis of TB infection. The pooled sensitivity was 78% (95% CI, 73% to 82%) for QuantiFERON-TB Gold and 90% (CI, 86% to 93%) for T-SPOT. TB [1]. The pooled specificity for both QuantiFERON and T-SPOT.TB was higher among nonBCG-vaccinated participants and among BCG-vaccinated participants. And thereby, IGRAs can be used to assist the diagnosis of LTBI [1] Especially in these regions with a high BCG vaccination rate, TST has a poor specificity due to false-positive responses, its advantages is more obvious [2].

The clinical value in the diagnosis and treatment of active TB

IGRAs for the definite diagnosis of active TB have no value [3]. Especially in high TB burden regions and settings, there are a high proportion of TB contacts among population, and the positive rate of IGRA is very high. Due to the inference of the false positive results caused by these TB contacts, the diagnostics performance of IGRA for active TB is low [4]. However, because IGRAs has a high sensitivity, it could be suitable for screening of TB. That is to say, if its result is negative, we may rule out the possibility of TB, which can reduce some unnecessary treatment.

As almost 20% of non-TB patients would be erroneously treated for TB and 25% of patients with tuberculous pleurisy would be missed, pleural fluid IGRA are not useful for the clinical diagnosis of tuberculous pleurisy [5]. IGRAs have limited value as diagnostic tools to screen and rule out Extra Pulmonary Tuberculosis (EPTB), especially in low/middle-income countries. The immune status of patients does not affect the diagnostic accuracy of IGRAs for EPTB [6]. However, because of poor diagnostic performance, consuming time and cost resources, IGRAs for therapeutic monitoring (reversion from positive to negative) didn’t show a clinical significance according to the previous data. [7]. Another study suggested that serial IGRA had limited use in children receiving antitubercular treatment [8].

The clinical value in the diagnosis of TB infection in HIVinfected patients

A prospective study that has been carried out in Spain revealed that IGRAs were more sensitive than TST for diagnosis of TB infection in HIV-infected patients, and dual sequential testing with TST and IGRAs may be the optimal approach for LTBI screening in this population [9]. However, another study believed that IGRAs perform similarly to the TST at identifying HIV-infected individuals with LTBI, and given that both tests have modest predictive value and suboptimal sensitivity, the decision to use either test should be based on country guidelines and resource and logistic considerations [10].

The clinical value in the diagnosis of TB infection in children

A meta-analysis in 2013 included in 31 studies calculated pooled estimates of sensitivities and specificities of QFT-G-IT, T-SPOT. TB, and TST. In this study, several sub-analysis were performed: stratification by background (low income vs. high income countries); including only microbiological confirmed TB cases; including only studies performing a simultaneous three-way comparison of the three tests, and including immunocompromised children. The results showed that both IGRAs showed no better performance than TST in low income countries [11].

Prospective Strategies

Currently some clinicians have a misunderstanding for IGRAs in some countries, it should make practical guidelines to TB diagnostic tools and further strengthen the training and guide for the doctors in the future, so as to more scientifically manage TB. However, currently available data on IGRAs is mainly from developed countries with low burden of TB, and the useful reports from the high burden countries is less available. The situation is different between them, and thereby it is urgent to perform largescale and better design studies to assess the clinical value of IGRAs in these regions. Funding This work is granted by the Social Development Technology Projects of Kunshan, Jiangsu, China (No. KS1011) and the National Natural Science Foundation of China (No. 81201253).

References

1. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008; 149: 177-184.

2. Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis. 2006; 10: 1192-1204.

3. Munoz L, Santin M. Interferon-gamma release assays versus tuberculin skin test for targeting people for tuberculosis preventive treatment: an evidencebased review. J Infect. 2013; 66: 381-387.

4. Zhu C, Liu Z, Li Z, Mei S, Hu Z. The performance and limitation of T-SPOT. TB for the diagnosis of TB in a high prevalence setting. J Thorac Dis. 2014; 6: 713-719.

5. Zhou Q, Chen YQ, Qin SM, Tao XN, Xin JB, Shi HZ. Diagnostic accuracy of T-cell interferon-gamma release assays in tuberculous pleurisy: a metaanalysis. Respirology. 2011; 16: 473-480.

6. Fan L, Chen Z, Hao XH, Hu ZY, Xiao HP. Interferon-gamma release assays for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis. FEMS Immunol Med Microbiol. 2012; 65: 456-466.

7. Chiappini E, Fossi F, Bonsignori F, Sollai S, Galli L, de Martino M. Utility of interferon-gamma release assay results to monitor anti-tubercular treatment in adults and children. Clin Ther. 2012; 34: 1041-1048.

8. Chiappini E, Bonsignori F, Mangone G, Galli L, Mazzantini R, Sollai S, et al. Serial T-SPOT.TB and quantiFERON-TB-Gold In-Tube assays to monitor response to antitubercular treatment in Italian children with active or latent tuberculosis infection. Pediatr Infect Dis J. 2012; 31: 974-977.

9. Ramos JM, Robledano C, Masia M, Belda S, Padilla S, Rodríguez JC, et al. Contribution of interferon gamma release assays testing to the diagnosis of latent tuberculosis infection in HIV-infected patients: a comparison of QuantiFERON-TB Gold In Tube, T-SPOT.TB and tuberculin skin test. BMC Infect Dis. 2012; 12: 169.

10. Cattamanchi A, Smith R, Steingart KR, Metcalfe JZ, Date A, Courtney Coleman, et al. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J Acquir Immune Defic Syndr. 2011; 56: 230-238.

11. Sollai S, Galli L, de Martino M, Chiappini E. Systematic review and metaanalysis on the utility of Interferon-gamma release assays for the diagnosis of Mycobacterium tuberculosis infection in children: a 2013 update. BMC Infect Dis. 2014; 14: S6.

Citation

Gao Y, Mei S, Wang J, Liu Z, Li Q, Gao Z, Zhu C and Sun Y. The Overview of the Clinical Significance of Interferon-Gamma Release Assays for the Diagnosis of Tuberculosis. SM J Pulm Med. 2015; 1(1): 1001.

Other Articles

Article Image 1

Obesity and Breathing Related Sleep Disorders: Concise Clinical Review

The increasing prevalence of obesity has lead to an increase in the prevalence of sleep disordered breathing in the general population. Obesity is a serious disorder resulting in significant health impairment. Obese adults are at increased risk of morbidity and mortality from acute and chronic medical conditions. Obesity is associated with anatomic alterations that predispose to upper airway obstruction during sleep. Obesity and sleep related breathing disorders occur to a particular subgroup that includes obese patients with hypoventilation correlated with Hypercapnic-OSA (obstructive sleep apnea), Hypercapnic-OSA with OHS (hypoventilation syndrome) and OHS without OSA.

OHS is a disease entity distinct from simple obesity and OSA. OSA is a common disorder. Obesity and particularly central adiposity are potent risk factors for OSA. They can increase pharyngeal collapsibility through mechanical effects on pharyngeal soft tissues and lung volume, and through central nervous system–acting signaling proteins (adipokines) that may affect airway neuromuscular control. Specific molecular signaling pathways encode differences in the distribution and metabolic activity of adipose tissue.

The OHS is characterized by the combination of obesity (BMI>30 kg/m2 ), daytime awake hypercapnia and hypoxemia , in the presence of sleep-disordered breathing without other known causes of hypoventilation, such as severe obstructive or restrictive parenchymal lung disease, kyphoscoliosis, severe hypothyroidism, neuromuscular disease, and congenital central hypoventilation syndrome. It is estimated that 90% of patients with OHS also have OSA. Patients with OSA typically have normal control of breathing and obesity is not a necessary condition; patients with OHS are morbidly obese, have hypoventilation during wakefulness with increased arterial PCO2 and decreased arterial PO2 , as well as nocturnal hypoventilation. The gold standard for the diagnosis is monitored polysomnography during sleep. In stable hypercapnic patients therapeutic choice will depend on two factors: underlying diagnosis (presence or absence of OSA) and severity of hypercapnia.

Ines Maria Grazia Piroddi¹, Sofia Karamichali², Cornelius Barlascini³, and Antonello Nicolini¹*


Article Image 1

Tracheal Diverticulosis Presenting as Chronic Cough

A 62 year old female patient with mild intermittent asthma was seen in the pulmonary clinic with a history of a productive cough for two years. She had required multiple courses of antibiotics over the past year. She underwent a CT scan of the chest which showed central bronchiectasis and multiple discrete diverticula projecting posteriorly from the membranous trachea measuring up to 2.3 x 1.7 x 1.7 cm.  The diverticula involved nearly the entire course of the trachea (Figure 1). A bronchoscopy was performed which showed tracheal pouches and indentations (Figure 2). There were no prior scans and therefore it is unclear for how long she had the diverticula. Her symptoms improved with antibiotics and she remains relatively well with chest physiotherapy and bronchial hygiene.

Humam Farah¹*, Parth Parikh¹, Michael Bukstein¹, and Ruxana T Sadikot²,³


Article Image 1

Emphyema Due to Hepatic Abscess

A 36 year-old man with previous biliary surgery due to pancreatitis with pseudo cyst formation five years earlier, had one week of right upper-quadrant pain. Although the pain was pleuritic, he had no respiratory symptoms and a normal chest radiograph.

Joseph R Shiber¹* and David Skarupa²


Article Image 1

Primary Soft-Tissue Nocardial Abscess with a Complication of Severe Pneumonia: A Case Report and Literature Review

Although very rare, nocardiosis is considered as an important opportunistic infection, especially in immunocompromised patients with long-term corticosteroid use or organ transplantation. Lung and skin involvements are frequent, but primary soft-tissue nocardiosis is very rare. Herein, we described a 48 year-old Chinese man with a primary soft-tissue nocardial abscess caused by multidrug-resistant nocardia asteroides, which was sensitive only to imipenem and resistant to trimethoprim-sulfamethoxazole and other antibiotics like amikacin and vancomycin.An initial treatment with a combination of surgical drainage and imipenem was conducted, but a secondary severe pneumonia was complicated two weeks later. Then, the antimicrobial regimen was shifted to sulbactam sodium/cefoperazone and itraconazole injection for the severe pneumonia. For nocardiosis, drainage was continued and minocycline was administered instead of imipenem for maintenance therapy for 9 months. Eventually, the patient recovered well from the primary soft-tissue nocardial abscess and the secondary severe pneumonia. To our knowledge, this is the first case with a combination of primary softtissue nocardial abscess, multidrug-resistant nocardia asteroides and complication of severe pneumonia.

Shufang Zhang¹#, Feifei Zhou²#, Xiuhui Lin³, Liuhong Wang⁴, Wei Cui³, and Gensheng Zhang³*


Article Image 1

Superior Vena Cava Obstruction in Lung Carcinoma

We report a case of Pancoast tumor with Superior vena cava obstruction and thoracic outlet syndrome in 60 year old patient who has been diagnosed to have undifferentiated lung carcinoma on evaluation. Patient was a chronic smoker from 40 years on treatment for chronic obstructive pulmonary disease and presented with hoarseness of voice, puffiness of face, pain in right arm and chest.

Chest radiography and computerized tomography of thorax showed homogenous density in right upper lobe extending in to superior mediastinum with involvement of multiple groups of lymphnodes. CT guided biopsy confirmed diagnosis of undifferentiated large cell carcinoma. Patient developed clinical features of superior vena caval obstruction in a period of 15 days.

Sreenivasa Rao Sudulagunta¹*, Shyamala Krishnaswamy Kothandapani², and Mahesh Babu Sodalagunta³


Article Image 1

The Role of Lung Function and the Importance to Measure Small Airways Modifications

Normally in clinical practice the evaluation of lung pathophysiology follows a functional and mechanical evaluation primarily through spirometry and plethysmography. The Small Airways (SAW) are one of the most important targets for respiratory diseases and various studies underline their strict relations with chronic diseases like asthma or COPD, although it is nowadays recognized their role in a lot of other pathological entities. The evaluation of SAW is not always easy and often more than one functional test must be done. So, the possibility to known the “scenario” of available functional respiratory tests, both in clinical and research setting, represents a central point in the respiratory world. Moreover the correct interpretation of the lung function tests is necessary not only to better evaluate the actual clinical status of the respiratory disorders but also to allow the appropriate therapeutic choice. The aim of the current review is to direct the readers attention to the importance of lung function evaluation and its specific role both in clinical and research setting.

Dejan Radovanovic¹,², Giovanni Marchese², and Pierachille Santus¹,²*


Article Image 1

Saber Sheath Trachea: Functional and Clinical Correlations

Saber sheath trachea refers to diffuse coronal narrowing of the intra-thoracic portion of the trachea with concomitant widening of the sagittal diameter. It is considered to be widely associated with Chronic Obstructive Pulmonary Disease (COPD). The diagnosis is based on the calculation of the tracheal index which is the ratio of coronal to sagittal length in the axial plane measured 1cm above the upper margin of the aortic arch. Saber sheath trachea is considered to be present when the tracheal index is less than 0.67. The tracheal index has been associated with severity of obstruction and most notably with hyperinflation and extent of emphysema in COPD patients. Thus, it can have clinical importance. The presence of saber sheath trachea and its clinical implications should be further explored in COPD as well as in other diseases in which emphysema represents a major component, as Combined Pulmonary Fibrosis Emphysema (CPFE).

Vasilios Tzilas¹ and Demosthenes Bouros¹*


Article Image 1

Impact of Poor Glycemic Control on Severity and Clinical Course of Chronic Obstructive Pulmonary Disease in Patients with Co-Existing Type 2 Diabetes Mellitus - One Year Prospective Study

Background: Chronic Obstructive Pulmonary Disease (COPD) and type 2 Diabetes Mellitus (DM) are common and under diagnosed chronic non-communicable medical conditions in India. The escalating epidemic of DM is a great challenge for the clinicians treating COPD as large number of patients have Poor Glycemic Control (PGC). We undertook this trial to study the influence of PGC on severity and disease outcome in COPD subjects with concomitant DM.

Materials and methods: COPD patients either known or newly diagnosed DM cases as per WHO criteria were enrolled in the study and grouped into patients with PGC and Optimal Glycemic Control (OGC) based on HbA1c measurements. Subjects were closely monitored for 1 year.

Results: Of the 490 subjects analyzed, 336 (68.57%) had PGC and 154 (31.43%) had OGC. COPD patients with PGC had more severe disease compared to OGC (Mean FEV1% predicted 48.47 ± 13.7 vs 67.4 ± 13.86, p= 0.0061) and also DOSE score (4.35 ± 1.88 vs 3.18 ± 2.30 p= 0.0052) at the baseline. After 1 year, patients with PGC had statistically significant high rates of exacerbations. The mean DOSE scores were statistically greater in PGC patients after 12 months suggesting worsening of COPD symptoms and quality of life. Hospitalization was significantly frequent and longer in PGC patients. (6.56 ± 1.70 vs 4.16 ± 1.26 p= 0.0004).

Conclusion: Patients with PGC had more severe COPD, poor lung function, high symptom score, and increased risk of exacerbations with frequent and prolonged hospitalizations.

Vinay Mahishale*, Ajith Eti, Bhagyashri Patil, Mitchelle Lolly, and Sujeer Khan


Article Image 1

Use of Telehealth Data in Multidisciplinary Team Review of COPD

Chronic Obstructive Pulmonary Disease (COPD) is a significant illness that lends itself well to telehealth – the remote monitoring of patients at home. Currently, COPD telehealth is usually led by community nurses. Given the multifaceted needs of patients with COPD, we argued that a Multidisciplinary Team (MDT) approach is a better way of holistically managing patients on telehealth. We present our experience of working as part of a community MDT to review patients already undergoing COPD telemonitoring. We collected data on the MDT activity during a six months period with the aim of highlighting deviations from best practice. The MDT prospectively reviewed 95 patients and issued 141 recommendations which were fed to the patient’s usual General Practitioner (GP) or directly implemented by the telehealth staff. We concluded that a multidisciplinary review of COPD telehealth patients is feasible and has the potential to add value to what is largely a technology-led service.

Ghassan A Hamad¹*, Michael Crooks², and Alyn H Morice³


Article Image 1

Home-Based System for Recording Pulmonary Function and Disease-Related Symptoms in Patients with Chronic Obstructive Pulmonary Disease, COPD - A Pilot Study

Introduction: Many patients with Chronic Obstructive Pulmonary Disease (COPD) suffer from acute exacerbations characterized by an increase in symptoms beyond normal day-to-day variation. The prognosis of patients with frequent exacerbations is poor and effort to curb these worsening episodes has great potential to improve the patient’s quality of life and to reduce associated costs. Telemonitoring has been proposed as a promising strategy in this respect. However, information on what physical signs or symptoms that should be recorded and how recorded data should be interpreted is largely missing in the literature.

Methods: A new home-based system, based on a tablet computer, which can guide COPD patients to perform spirometry (inspiratory capacity, IC and forced expiratory volume in one and six seconds, FEV1 and FEV6) and record symptoms (COPD assessment test, CAT) was developed. The system was evaluated for 8-12 weeks in four patients with moderate to severe COPD with the aims to; i) assess the feasibility of the system to be used unsupervised by COPD patients and, ii) to evaluate the quality and ability of recorded parameters to reveal early signs of an exacerbation. Pearson bivariate correlation was performed between all outcome measures and descriptive information about inherent subject properties were presented.

Results: The system was well accepted by all study subjects and the study generated a total of 253 measurements of which 94.5% were considered acceptable for analysis. One of the subjects developed an acute exacerbation towards the end of the study, whereas the other three subjects remained stable. Descriptive analysis of the data suggest that trends in the CAT score may indicate changes in health status and that IC tends to be more responsive to these changes compared to FEV1.

Conclusion: The system developed in this study is well suited to be used unsupervised by COPD patients. Recorded data, in particular CAT, may be sensitive enough to detect early signs of an acute COPD exacerbation, although more data is needed to fully resolve the nature of such an association.

Ohberg F¹*, Karin Wadell², Anders Blomberg³, Kenji Claesson⁴, Urban Edstrom⁵, and Asa Holmner⁶